Downloading...
Download

ROIV

Roivant Sciences (ROIV): A Multibagger Stock Opportunity Roivant Sciences (ROIV) is poised for significant growth with a strong pipeline, including potential blockbusters like Batoclimab and Brepocitinib in the autoimmune space. Recent deals, including the $5.2B sale of Telavant, have strengthened their balance sheet and set the stage for future profitability. Upcoming Q4 catalysts, a $1.5B buyback program, and a solid focus on pulmonary hypertension therapies make ROIV an undervalued gem at its current price. Personal Note: Hi, I'm sharing insights on stocks with strong catalysts like ROIV. Follow me for more deep dives and stock picks.
NASDAQ:ROIVLong
by InvestOhTrader
Nutrix Therapeutics ( NRIX) has momentum for earnings LONGNRIX , on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. It printed a "big ass" green engulfing candle to finish the week. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, price fell about 25% in 2023. earnings have been both line beats but the negative cash flow remains as a challenge. The volume and volatility show both are heightened in the pre-earnings run- up. . This is a risky earnings play, NRIX does not yet make money like many other young biotechnology companies trying to grow However, because it lost less than forecasted, buyer interest has increased. There is an absence of any options volume and so illiquidity prevents consideration of options trading. I suspect a long trade in shares may gain to $14 targeting the pivot highs of April 23 and November 22 for projected gain upside of about 65% ( stop loss of 2.5%) If earnings disappoint trader expectations and price fades I will stop out with a loss of about 2.5% This makes this long swing trade a projected 2.5 /65 a R:r of 25 which validates it as a conservative trade if taking only 5% or less of buyer power applied to the risk. Biotechnology is expected to be one of the hottest subsectors of 2024. This could be one of them.
NASDAQ:NVAXLong
by AwesomeAvani
RZLT Biotechnology Penny Stock Reports in the next day LONGRZLT is a biotechnology company which has products in clinical development. Many are aware that means rigorous clinical trials before an FDA approval and a product line that generates earnings. Stock price is more about growth and potential more than anything else. That said the chart looks good and I sense there is momentum heading into earnings in the next day so this is a buy for me. I can see that price broke above a recent supply/resistance zone. This penny stock likely cannot be shorted so there is no selling pressure to be exerted until present longs have found their target. This can add to the momentum without the drag of that short selling. A penny here and a penny there it all adds up over time especially with compounding in active trading with penny stocks that have great range.
NASDAQ:RZLTLong
by AwesomeAvani
2
ROIV - BioTech reporting 2/13 as a LONG earnings tradeRoivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and volatility show both are heightened in the pre-earnings run- up. The last report in November was a double beat which is good prognosis for the one upcomings. This is a risky earnings play, ROIV does not yet make money. However, because it lost less than forecasted, buyer interest has increased. The call option for 2/16 for a strike of $12.50 is priced at $ 5.00 per contract. I suspect a long trade in shares may gain to $ 11.50 targeting the double top at the turn of the year for a projected gain upside of about 7% (with a stop loss of 2.5%). Considering that ROIV has gained 12% this past week, 7% in the next two days is about the same trend angle. As to the call contract, I have considered 100% return as my expections for the two days before the earnings. If earnings disappoint trader expectations and price fades I will sell to close the contract. If earnings is as expected, I will roll the contract forward into the March monthly and add a bit more capital into the trade.
NASDAQ:ROIVLong
by AwesomeAvani
1